Astellas Pharma Inc.
ALPMY · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $2,602,971 | $2,927,195 | $3,430,258 | $3,505,860 |
| - Cash | $188,372 | $335,687 | $376,840 | $315,986 |
| + Debt | $831,426 | $920,016 | $200,007 | $212,744 |
| Enterprise Value | $3,246,025 | $3,511,524 | $3,253,425 | $3,402,618 |
| Revenue | $1,912,323 | $1,603,672 | $1,518,619 | $1,296,163 |
| % Growth | 19.2% | 5.6% | 17.2% | – |
| Gross Profit | $1,563,117 | $1,311,187 | $1,191,830 | $1,014,871 |
| % Margin | 81.7% | 81.8% | 78.5% | 78.3% |
| EBITDA | $248,046 | $194,814 | $246,878 | $241,519 |
| % Margin | 13% | 12.1% | 16.3% | 18.6% |
| Net Income | $50,747 | $17,045 | $98,714 | $124,086 |
| % Margin | 2.7% | 1.1% | 6.5% | 9.6% |
| EPS Diluted | 28.24 | 9.47 | 54.09 | 67.05 |
| % Growth | 198.2% | -82.5% | -19.3% | – |
| Operating Cash Flow | $194,512 | $172,475 | $332,325 | $258,160 |
| Capital Expenditures | -$57,330 | -$82,497 | -$88,541 | -$76,448 |
| Free Cash Flow | $137,182 | $89,978 | $243,784 | $181,712 |